3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

No abstract is available for this paper.

• Publication year

  1975

• Venue

  Life Science

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 1143006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain serotonin content: physiological regulation by plasma neutral amino acids.

  1997cited by this paper
• Rat brain regional uptake and decarboxylation of L-DOPA following carotid injection.

  1975cited by this paper
• Regional distribution of catecholamines in rat brain after L-3-O-methyldopa and L-dopa.

  1974cited by this paper
• Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's disease

  1974cited by this paper
• “On‐off” phenomenon with levodopa therapy in parkinsonism

  1974cited by this paper
• Nutrition and the brain.

  1974cited by this paper
• Brain blood flow in the conscious and anesthetized rat.

  1973cited by this paper
• 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.

  1973cited by this paper
• 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.

  1972cited by this paper
• Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

  1972cited by this paper
• The metabolic pathways of L-3-O-methyldopa.

  1972cited by this paper
• A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients.

  1972cited by this paper
• Nature and roles of receptor sites for amino acid transport.

  1972cited by this paper
• Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa.

  1971cited by this paper
• Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.

  1971cited by this paper
• The metabolism of L‐3–0‐methyldopa, aprecursor of dopa in man

  1971cited by this paper
• l-DOPA treatment in Parkinson's disease: Effect on dopamine and related substances in discrete brain regions

  1971cited by this paper
• Distribution and metabolism of l‐3‐O‐methyldopa in rats

  1970cited by this paper
• Drug-induced changes of extracerebral dopa metabolism in man.

  1969cited by this paper
• Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.

  1968cited by this paper
• A comparison of the transport systems for amino acids in brain, intestine, kidney and tumour.

  1968cited by this paper
• DOPAMINE FORMATION IN BRAIN CAPILLARIES—AN ENZYMIC BLOOD–BRAIN BARRIER MECHANISM

  1967cited by this paper
• REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐I

  1966cited by this paper
• DISTINCT MEDIATING SYSTEMS FOR THE TRANSPORT OF NEUTRAL AMINO ACIDS BY THE EHRLICH CELL.

  1963cited by this paper
• Uptake of tyrosine by rat brain in vivo.

  1960cited by this paper

• Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment.

  2024cites this paper
• Chronic prostatitis/chronic pelvic pain syndrome induces metabolomic changes in expressed prostatic secretions and plasma

  2024cites this paper
• Neurodegenerative Etiology of Aromatic L-Amino Acid Decarboxylase Deficiency: a Novel Concept for Expanding Treatment Strategies

  2023cites this paper
• Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

  2023cites this paper
• Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease

  2023cites this paper
• Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications

  2021cites this paper
• Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives

  2018cites this paper
• UPSALIENSIS UPPSALA 2018 Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1437 New Approaches for Levodopa Treatment in Parkinson ’ s Disease MARINA

  2018cites this paper
• Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review

  2018cites this paper
• Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics

  2017cites this paper
• Glutathione-decorated dendrons as potential drug carrier systems in Multiple Sclerosis

  2017cites this paper
• Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis.

  2017cites this paper
• Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects

  2016cites this paper
• 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA

  2016cites this paper
• Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study

  2015cites this paper
• Effect of opicapone on levodopa pharmacokinetics, catechol‐O‐methyltransferase activity and motor fluctuations in patients with Parkinson's disease

  2015cites this paper
• Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

  2014cites this paper
• Nanostructures: a platform for brain repair and augmentation

  2014cites this paper
• Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition

  2014cites this paper
• Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

  2013cites this paper
• Chapter 7 In vivo biodistribution of prion-and GM 1-targeted polymersomes following intravenous administration in mice

  2012cites this paper
• In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.

  2012cites this paper
• Modern methods for delivery of drugs across the blood-brain barrier.

  2012cites this paper
• Development of neuropeptide drugs that cross the blood-brain barrier

  2011cites this paper
• Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.

  2011cites this paper
• A New Mixture Design‐Based Approach to Graphical Screening of Potential Interconnections and Variability Processes in Metabolic Systems

  2010cites this paper
• Caffeic acid improves the bioavailability of l‐dopa in rabbit plasma

  2010cites this paper
• Levodopa in Parkinson's disease: from the past to the future

  2010cites this paper
• The Role of the Blood-Brain Barrier

  2009cites this paper
• Delivery of peptide and protein drugs over the blood-brain barrier.

  2009cites this paper
• The effects of entacapone on cardiorespiratory, autonomic, and clinical responses in L-dopa-treated patients with Parkinson's disease

  2006cites this paper
• Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA.

  2006cites this paper
• Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior

  2005cites this paper
• Central action of benserazide after COMT inhibition demonstrated in vivo by PET

  2005cites this paper
• The mechanism of perturbation in monoamine metabolism by L-DOPA therapy: in vivo and in vitro studies

  2005cites this paper
• Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

  2004cites this paper
• Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

  2004cites this paper
• Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease

  2004cites this paper
• Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.

  2003cites this paper
• Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).

  2003cites this paper
• Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson’s disease

  2003cites this paper
• Comparative Single- and Multiple-Dose Pharmacokinetics of Levodopa and 3-O-Methyldopa following a New Dual-Release and a Conventional Slow-Release Formulation of Levodopa and Benserazide in Healthy Volunteers

  2002cites this paper
• Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.

  2002cites this paper
• COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease

  2002cites this paper
• Monitoring of L-dopa concentrations in Parkinson's disease.

  2001cites this paper
• Tolcapone increases maximum concentration of levodopa

  2000cites this paper
• Catechol O-Methyltransferase: Glucuronidation of Inhibitors and Methylation of Substrates

  2000cites this paper
• Theoretical pharmacokinetic and pharmacodynamic simulations of drug delivery mediated by blood–brain barrier transporters

  2000cites this paper
• Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

  2000cites this paper
• L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4.

  1999cites this paper
• Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells.

  1999cites this paper
• Monoamine oxidase and catechol-O-methyltransferase inhibitors.

  1999cites this paper
• Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.

  1999cites this paper
• Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: an application of the Dixon equation.

  1999cites this paper
• New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

  1999cites this paper
• Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.

  1998cites this paper
• Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone

  1998cites this paper
• Advances in the treatment of Parkinson's disease.

  1998cites this paper
• Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.

  1998cites this paper
• Striatal 6‐[18F]fluorodopa accumulation after combined inhibition of peripheral catechol‐O‐methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction

  1997cites this paper
• Synthesis and in vitro evaluation of two progressive series of bifunctional polyhydroxybenzamide catechol-O-methyltransferase inhibitors.

  1997cites this paper
• Separation of DL-dopa by means of micellar electrokinetic capillary chromatography after derivatization with Marfey's reagent.

  1997cites this paper
• Emerging treatments in Parkinson's disease.

  1997cites this paper
• Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.

  1997cites this paper
• The kinetic behaviour of [3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms.

  1997cites this paper
• Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

  1997cites this paper
• New drugs in the treatment of Parkinson's disease. An introduction.

  1996cites this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  1996cites this paper
• Studies on the pharmacology of the inward transport of L‐DOPA in rat renal tubules

  1996cites this paper
• Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.

  1995cites this paper
• Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease

  1995cites this paper
• L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism.

  1995cites this paper
• A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease

  1995cites this paper
• Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

  1995cites this paper
• Cell inward transport of l‐DOPA and 3‐O‐methyl‐l‐DOPA in rat renal tubules

  1994cites this paper
• The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP+-lesioned mice

  1994cites this paper
• Mid-stage parkinsonism with mild motor fluctuations.

  1994cites this paper
• Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

  1994cites this paper
• Effect of brief levodopa holidays on the short‐duration response to levodopa

  1994cites this paper
• Simultaneous in vivo microdialysis in plasma and skeletal muscle: a study of the pharmacokinetic properties of levodopa by noncompartmental analysis.

  1994cites this paper
• 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.

  1994cites this paper
• The effect of entacapone (OR‐611) on brain [18F]‐6‐L‐fluorodopa metabolism

  1994cites this paper
• New and emerging strategies for improving levodopa treatment.

  1994cites this paper
• Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

  1994cites this paper
• Striatal L‐DOPA Decarboxylase Activity in Parkinson's Disease In Vivo: Implications for the Regulation of Dopamine Synthesis

  1993cites this paper
• The effect of age on concentrations of monoamines, amino acids, and their related substances in the cerebrospinal fluid

  1993cites this paper
• The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

  1993cites this paper
• Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.

  1993cites this paper
• Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects

  1993cites this paper
• Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.

  1993cites this paper
• COMT inhibitors and metabolism of fluorodopa enantiomers in aggregating cell cultures

  1993cites this paper
• Drug delivery to brain and the role of carrier-mediated transport.

  1993cites this paper
• Estimation of regional cerebral utilization of [11C]‐L‐3, 4‐dihydroxy‐phenylalanine (DOPA) in the primate by positron emission tomography

  1992cites this paper
• 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain

  1992cites this paper
• Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors.

  1992cites this paper
• Treatment strategies for extension of levodopa effect.

  1992cites this paper
• Distribution and Kinetics of 3-O-Methyl-6-[18F]fluoro-L-DOPA in the Rhesus Monkey Brain

  1991cites this paper
• In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle

  1991cites this paper
• (−)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity

  1991cites this paper
• Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.

  1991cites this paper